Abstract: The present invention provides a compound of Formula III: Formula III wherein A is: and Z, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, which is useful for treating Alzheimer's disease.

Abstract: The present invention provides a compound of Formula I: wherein R is H or F; and A is: or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound of Formula III: wherein A is: and Z, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound of Formula I: wherein R is H or F; and A is: or a pharmaceutically acceptable salt thereof.

Abstract: Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds from an isomerically pure starting material are described. In particular, methods of preparing a 3-(1-(dimethylamino)-2-methylpentane-3-yl)phenol as a substantially optically pure (R,R) stereoisomer are described. Using a method of the present invention, only the (R,R) and (S,S) stereoisomers of the target compound are produced, increasing the yield and stereoselectivity of the desired (R,R) stereoisomer.

Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound of Formula I: Formula I wherein R is H or F; and A is: or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound of Formula I: wherein R is H or F; and A is: or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

Abstract: A four-valve per cylinder engine has two intake valves, two exhaust valves and a centrally located fuel injector. Between each adjacent pair of valves is a valve bridge with a point of minimum separation between adjacent valves. In the present disclosure, the glow plug port is defined in the cylinder top at a location outboard of the minimum separation between adjacent and at a depth which is tangent to an edge of a fuel jet emanating the injector. By placing the glow plug farther outboard than found in the prior art, the glow plug contacts the fuel as it comes out of the injector and as it rebounds off a feature of the piston bowl.

Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides novel processes for making ethyl-4-cyano-3-hydroxybutyrate, e.g., (R)-ethyl 4-cyano-3-hydroxybutyric acid, and 4-cyano-3-hydroxybutyric acid. The invention provides protocols for making and 4-cyano-3-hydroxybutyric acid and ethyl-4-cyano-3-hydroxybutyrate by whole cell processes, cell lysate processes, “one pot processes” and “multi-pot” processes using a variety of parameters.

Abstract: A method of forming at least one electronic device on a substrate comprising creating a depository and an attached capillary; providing a liquid containing particles in the range 1 nanometer to 1 millimeter for deposit into the depository; the liquid flowing into the at least one capillary by capillary action; evaporating the liquid such that the particles form an agglomerate beginning at the end of the at least one capillary with a substantially uniform distribution of the particles within the agglomerate; whereby the agglomerate is used to form a part of the at least one electronic device. An microelectronic integrated circuit device comprising a substrate; a depository coupled to said substrate formed by at least one wall, a capillary channel coupled to said depository adapted to be filled with liquid comprising nanoparticles by capillary action, whereby as the liquid evaporates, an agglomerate forms in the capillary channel having a substantially uniform distribution of the particles.

Abstract: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12; R9 is selected from H —NR13C(O)R14 and —C(O)NR10R11; R12 is selected from H, C1-C6 alkyl and C3-C6 cycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

Abstract: A method for quieting noise and vibration from a crankcase of an engine comprises dispersing a first amount of elemental carbon in a second amount of lubricant oil to yield a concentrated elemental-carbon suspension. The method further comprises adding the concentrated elemental-carbon suspension in an amount effective to quiet the noise and vibration to a third amount of lubricant oil in the crankcase.

Abstract: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12, R9 is selected from H and —C(O)NR1OR1 1, R12 is selected from H, C1-C6 alkyl and C3-C6 cycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

Abstract: A wagering game system and its operations are described herein. In some embodiments, the operations can include providing gaming content for use during a bingo game, where the gaming content includes a representation of a bingo game card that includes card identifiers, arranged in a distinct pattern, which are usable during the bingo game to track game identifiers, with equivalent values, when drawn during the bingo game. The operations can further include selecting a card identifier, in response to user input, which indicates a user prediction that a corresponding game identifier, with an equivalent value, will be drawn during the bingo game. The operations can further include placing a bet for a secondary wagering game on the selecting of the card identifier, detecting a draw of the corresponding game identifier during the bingo game, and using the draw of the game identifier as an outcome for the bet.

Abstract: An integrated engine cover and exhaust gas recirculation cooler for an internal combustion engine includes a cover for enclosing a portion of an engine and an EGR cooler having a housing formed as one piece with the cover. The EGR cooler includes at least one cooler section located within the housing and EGR and bypass valves for controlling the flow of exhaust gases either though the cooler or around the cooler.